Radiogenomic profiling of prostate tumors prior to external beam radiotherapy converges on a transcriptomic signature of TGF-β activity driving tumor recurrence

Competing Interest Statement

Y.L. and E.D. are employees of Veracyte, Inc. A.G.S. reports that the National Cancer Institute (NCI) has a Cooperative Research and Development Agreement (CRADA) with Astellas. Resources are provided by this CRADA to the NCI. A.G.S. gets no personal funding from this CRADA but is the primary investigator of the CRADA. B.J.W. reports that the National Institutes of Health (NIH) has a CRADA with Philips, that NIH has intellectual property (IP) in the prostate cancer space, and has licensed IP to Philips. NIH receives royalties from Philips for patent licensing related to, a portion of which is shared with B.J.W. B.J.W. reports that NIH and NVIDIA have a CRADA. The remaining authors declare no conflicts of interest.

Clinical Trial

NCT01834001, NCT02307058

Funding Statement

This work was supported by the Prostate Cancer Foundation (Young Investigator Award to A.T.K.), Department of Defense Congressionally Directed Medical Research Program (Prostate Cancer Research Program Early Investigator Award W81XWH-22-1-0067 to A.T.K.), the National Cancer Institute (Sylvester Cancer Center Support Grant P30 CA240139 and U01CA239141 to R.S. and A.P.), and the Intramural Research Program of the NIH, National Cancer Institute. These funding bodies had no role in the design of the study and collection, analysis, and interpretation of data, nor in writing the manuscript.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Institutional Review Boards of the National Institutes of Health and the University of Miami Sylvester Cancer Center gave ethical approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes